TRASTUZUMAB

作品数：119被引量：282H指数：9
导出分析报告
相关领域：医药卫生更多>>
相关作者：孙治国郭亚军钟延强高洁张翮更多>>
相关机构：第二军医大学中山大学复旦大学附属肿瘤医院南京军区南京总医院更多>>
相关期刊：更多>>
相关基金：国家自然科学基金北京市自然科学基金云南省教育厅科学研究基金国家重点基础研究发展计划更多>>
-
在结果中检索

检索结果分析

结果分析中...
共 条 记 录，以下是1-10
全选清除导出
参考文献引证文献引用追踪
视图：
排序：
Apple polyphenol phloretin inhibits typeⅡglucose transporter and enhances anti-HER2 antibody drug binding as an adjuvant treatment for HER2-positive breast cancer
《Food Science and Human Wellness》2025年第4期1264-1280,共17页Han-Sheng Chang Tzu-Chun Cheng Shih-Hsin Tu Pei-Han Liao Yu-Ching Lee Chi-Tang Ho Min-Hsiung Pan Li-Ching Chen Yuan-Soon Ho 
supported by the Science and Technology Council,Taiwan,China(NSTC 112-2320-B-039-057 and MOST 111-2320-B-039-067-MY3);the China Medical University,Taiwan,China(CMU112-S-18),awarded to Yuan-Soon Ho;the China Medical University,Taiwan,China(CMU112-N-02),awarded to Li-Ching Chen;the Science and Technology Council,Taiwan,China(MOST 110-2320B-039-079)。
This study presents novel findings on the potential of phloretin,an apple polyphenol,to enhance the effectiveness of anti-human epidermal growth factor receptor-2(HER2)antibody therapy in HER2-positive breast cancer p...
关键词：TypeⅡglucose transporter(GLUT2) PHLORETIN Human epidermal growth factor receptor 2-intracellular domain(HER2-ICD) TRASTUZUMAB Trastuzumab-resistance 
A recombinant fragment antigen-binding(Fab)of trastuzumab displays low cytotoxic profile in adult human cardiomyocytes:first evidence and the key implication of FcγRIIA receptor
《Acta Pharmacologica Sinica》2025年第3期618-631,共14页Anna De Bartolo Naomi Romeo Alessandro Marrone Vittoria Rago Maria Concetta Granieri Maria Luigia Vommaro Arianna Cupelli Maria Carmela Cerra Cesare Indiveri Raffaele Ronca Maria Cantile Riccardo Sanna Carmine Rocca Tommaso Angelone 
supported by“SI.F.I.PA.CRO.DE.–Sviluppo e industrializzazione farmaci innovativi per terapia molecolare personalizzata PA.CRO.DE”(PON ARS01_00568).
Fragment crystallizable gamma receptors(FcγRs)mediate various cellular responses with significant cardiovascular implications.They contribute to the anticancer activity of trastuzumab(TRZ),a recombinant humanized mon...
关键词：cardiac complications TRASTUZUMAB rFab-HER2 Fc region FcyRIIA HER2 
Programmed cell death receptor 1 inhibitor Pembrolizumab in the treatment of advanced gastric cancer
《World Journal of Gastrointestinal Surgery》2025年第2期16-19,共4页Xue-Mei Yi Hong-Qiao Cai Yan Jiao 
Supported by Jilin Provincial Natural Science Foundation,No.YDZJ202401650ZYTS。
This editorial discusses Christodoulidis et al's article,which appeared in the most recent edition.The clinical trials have demonstrated the programmed cell death receptor 1(PD-1)inhibitor Pembrolizumab involved combi...
关键词：Programmed cell death receptor 1 inhibitor Pembrolizumab Advanced gastric cancer CHEMOTHERAPY TRASTUZUMAB 
Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer
《四川生理科学杂志》2025年第1期145-145,共1页Charles E Geyer Jr 
Background:Patients with human epidermal growth factor receptor 2(HER2)-positive early breast cancer with residual invasive disease after neoadjuvant systemic therapy have a high risk of recurrence and death.The prima...
关键词：SURVIVAL CANCER BREAST 
PTPN9 regulates HER3 phosphorylation during trastuzumab treatment and loss of PTPN9 is a potential biomarker for trastuzumab resistance in HER2 positive breast cancer
《Cancer Communications》2025年第1期68-73,共6页Abul Azad Maryam Arshad Daniele Generali Katharina Feldinger Merel Gijsen Carla Strina Mariarosa Cappelletti Daniele Andreis Russell Leek Syed Haider Pirkko-Liisa Kellokumpu-Lehtinen Ioannis Roxanis Adrian Llewellyn Harris Abeer Mahmoud Shaaban Heikki Joensuu Anthony Kong 
supported by Breakthrough Breast cancer(Grant number:CSFKong)through Holbeck Charitable Trust;Prof A Shaaban is supported by Birmingham CRUK Centre grant.
Although trastuzumab does not bind to human epidermal growth factor receptor 3(HER3),it dephosphorylates HER3 through a previously unknownmechanism.In addition,HER3 is reactivated during prolonged trastuzumab treatmen...
关键词：HER3 TRASTUZUMAB TREATMENT HER2 PTP 
Clinical Analysis of Trastuzumab-Targeted and Chemotherapy Treatment for Breast Cancer Patients
《Proceedings of Anticancer Research》2024年第6期73-79,共7页Ying Liang 
Yunnan Provincial Department of Education Scientific Research Fund Project“Research on the Construction of Antibody-Drug Conjugate MMAF-Trastuzumab and Its Biological Function in Inhibiting Breast Cancer”(Project No.2024J0227)。
Objective: To explore the clinical effectiveness and safety of trastuzumab combined with chemotherapy in breast cancer patients. Methods: Eighty patients with postoperative local recurrence of breast cancer were divid...
关键词：Breast cancer TRASTUZUMAB Targeted therapy CHEMOTHERAPY Clinical treatment efficacy 
Navigating the implementation gap for Trastuzumab’s journey from health insurance to patient access:a preliminary study in a hospital in China
《Global Health Research and Policy》2024年第1期45-56,共12页Xingxia Yang Yufei Jia Jianhong Xu Qin Zhou Qian Long Yi Yang Yunguo Liu Juanying Zhu Xiaochen Zhang 
The research results of this article(or publication)are sponsored by the Kunshan Municipal Government(23KKSGR015)research funding.
Background Trastuzumab,a monoclonal antibody for breast cancer,faces global accessibility challenges,primarily due to high costs.This study examines how changes in medical insurance policies and price adjustments infl...
关键词：Breast cancer Trastuzumab utilization and accessibility FISH test Basic medical insurance coverage 
Uptake of biosimilars in China:a retrospective analysis of the case of trastuzumab from 2018 to 2023
《Global Health Research and Policy》2024年第1期139-150,共12页Qiyou Wu Zhitao Wang Yihan Fu Ren Luo Jing Sun 
Peking Union Medical College[Fund(2019)No.22]。
Background The Chinese biosimilar industry has demonstrated rapid growth in recent years.Limited evidence is available about biosimilar uptake at the national level.This study aimed to assess biosimilar uptake in the ...
关键词：BIOSIMILARS TRASTUZUMAB Market dynamics Market competitions UPTAKE 
BIRC3 induces the phosphoinositide 3-kinase-Akt pathway activation to promote trastuzumab resistance in human epidermal growth factor receptor 2-positive gastric cancer
《World Journal of Gastrointestinal Oncology》2024年第11期4436-4455,共20页Shu-Liang Li Pei-Yao Wang Yang-Pu Jia Zhao-Xiong Zhang Hao-Yu He Peng-Yu Chen Xin Liu Bang Liu Li Lu Wei-Hua Fu 
the Tianjin Municipal Education Commission Scientific Research Project,No.2018KJ055.
BACKGROUND Trastuzumab-targeted therapy is currently the standard of care for advanced human epidermal growth factor receptor 2(HER2)-positive gastric cancer.However,the emergence of resistance to trastuzumab poses si...
关键词：Gastric cancer Human epidermal growth factor receptor 2 TRASTUZUMAB DRUG-RESISTANCE BIRC3 
Inetetamab combined with S-1 and oxaliplatin as first-line treatment for human epidermal growth factor receptor 2-positive gastric cancer
《World Journal of Gastroenterology》2024年第40期4367-4375,共9页Ying Kong Qi Dong Peng Jin Ming-Yan Li Li Ma Qi-Jun Yi Yu-E Miao Hai-Yan Liu Jian-Gang Liu 
Supported by China Scientific Research Fund for HER2 Target from China Anti-Cancer Association,No.CORP-239-M9.
BACKGROUND Patients with human epidermal growth factor receptor 2(HER2)-positive advanced gastric cancer have poor outcomes.Trastuzumab combined with chemotherapy is the first-line standard treatment for HER2-positive...
关键词：Human epidermal growth factor receptor 2-positive Advanced gastric cancer Inetetamab TRASTUZUMAB EFFICACY Safety 
全选清除导出
共13页<12345678910>
检索报告 对象比较 聚类工具 使用帮助 返回顶部